Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
And AbbVie and Genmab scoop their ASH presentation with new data.
The company adds royalty aggregation to its R&D business.
But Enhertu is coming.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
